Journal article
Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138 769 individuals
Abstract
BACKGROUND: Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARBs) reduce cardiovascular disease (CVD) events, but a recent meta-analysis of selected studies suggested that ARBs may increase cancer risks.
OBJECTIVE: Candesartan, irbesartan, telmisartan, valsartan, and losartan were assessed for incident cancers in 15 large parallel long-term multicenter double-blind clinical trials of these agents involving …
Journal
Journal of Hypertension, Vol. 29, No. 4, pp. 623–635
Publisher
Wolters Kluwer
Publication Date
4 2011
DOI
10.1097/hjh.0b013e328344a7de
ISSN
0263-6352